Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer

VernacularTitle:血清炎性标志物对非小细胞肺癌免疫治疗的预测价值
Author: Hong LUO ¹ ; Hong YIN ; Guangyue HU ; Hong TAO
Author Information

1. 苏州大学附属第一医院肿瘤科，苏州　215000
Keywords: Carcinoma, non-small-cell lung; Immunotherapy; Inflammatory markers
From: Journal of International Oncology 2022;49(3):177-180
CountryChina
Language:Chinese
Abstract: Immune checkpoint inhibitors (ICIs) can not only prolong the survival time of patients with non-small cell lung cancer (NSCLC) in a short time, but also achieve a lasting response to the tumor. However, there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC, and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment. Inflammation has played a definite role in the occurrence and development of tumors, and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status, such as lactate dehydrogenase, C-reactive protein, serum neutrophils, lymphocytes, platelets and other indicators. These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors.